about
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.A method for assessing age-time disease incidence using serial prevalence data.Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudies.Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyPregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships.Estimation of adjusted rate differences using additive negative binomial regression.Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.Using time of first positive HIV test and other auxiliary data in back-projection of AIDS incidence.Simultaneous back-projection of AIDS incidence data for two or more groups.Fitting a multiplicative incidence model to age- and time-specific prevalence data.A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.Meta-analysis of clinical trials with early stopping: an investigation of potential bias.A randomized controlled trial of exercise and manipulative therapy for cervicogenic headache.The association between El Niño/Southern Oscillation events and typhoons in the Marshall Islands.Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines.Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping.Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes.Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.Parametric conditional frailty models for recurrent cardiovascular events in the lipid study.Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes.Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.Determining the size of a cross-sectional sample to estimate the age-specific incidence of an irreversible disease.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Relative risk regression: reliable and flexible methods for log-binomial models.Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, fluo-3.Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with TemsirolimusPulse Oximeter Saturation Targeting and Oximeter Changes in the Benefits of Oxygen Saturation Targeting (BOOST)-II Australia and BOOST-II UK Oxygen TrialsLamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trialProgression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysisLombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in IndonesiaDecreasing age at infection for homosexually acquired HIV in Italy: results of a back-calculation analysisGuidelines for the design of clinical trials with longitudinal outcomesClinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biasesBaseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapyOptimal design of clinical trials comparing several treatments with a controlBiases in the identification of risk factor thresholds and J-curvesAssessment of statistical heterogeneity in the PLATO trialFlexible regression models for rate differences, risk differences and relative risks
P50
Q27853328-E54C2154-0E50-463B-9B1D-4349664B3DDFQ32154197-97465B3E-DA04-439F-AE8C-4C68D0C26E1EQ33224981-C57DE6CF-AA6C-4A95-AEB0-9E418AF329B3Q33548159-BC547D38-D115-47DE-B680-01CD3D28DB26Q33735269-C1E92E28-B40D-4A81-9DB6-BF733D14F6FEQ35987990-4592B337-5252-4D65-8168-EF9136873CF5Q36334253-AA4A7A75-DA71-48DB-9F79-06F6D929478FQ36714822-6B935415-54AB-4340-8FA6-520ECB2EEA3EQ36730576-EF347353-0611-4BD2-A9E8-221A826C4829Q36803961-0996D57A-FA3A-46AC-B949-D5ACD71D2FEBQ37873051-6856D710-B8ED-4F2C-A5E3-20F067E8ADFDQ38119200-E91984D5-F7FE-4855-8C75-0878CC1D3B56Q39403272-2713E884-2E68-4B9E-85D5-27EC71B0870EQ40975129-52950B66-EA5E-4360-9593-DB0CB624F090Q41587037-3E3E759C-DB09-4F01-9F61-E2001C725458Q41719521-99F1DC95-DEBC-4DE5-82AF-729E20554EFBQ42654642-659C8DD9-B136-40C2-8E4A-E3C0CAF6EB68Q43009311-AC410A4B-2817-4A84-8071-BDAADAF9652FQ43447183-17E94136-C01E-4E10-A375-A5B31033B9B0Q44446094-0CFBF762-13CE-476D-9CFF-ECBEDE66AEA0Q44878979-BAE69E7E-9367-4B51-A252-7F437EDE2DBDQ47366340-2D18367B-40FA-4A3C-88CD-ADCA9049B4F6Q49979586-C0764E7D-09C4-4DF4-A5E2-290C158B8D3AQ51532419-69EF5DB3-17D5-4EEE-9D26-2717D1E5ACD4Q52690105-C154BED5-E4C0-427D-AC42-341F55EF9F0FQ54119257-7A048C8A-5FBD-4FF0-B6B2-C4ACE34FDCBCQ54254503-7CC6BD87-869F-4335-B362-2EC3EED73476Q57311268-EEE35879-7FBF-437C-AF4D-D0F319789077Q57480444-531C7DA5-ECD4-453A-A7BC-16F2823B4724Q57880669-248FC26D-364F-4580-92C3-02A1F757A547Q58799481-1A68339C-C9BD-4CD6-AB0E-690582EEB613Q72515387-7E728892-2CFF-4C1D-8386-3F74BAB06036Q74225328-6E83271A-B686-4D35-8CBF-DF292292B66EQ74268574-A38CE569-0BA8-45DE-BB6F-C988E48F2C21Q74605050-FE07C7DC-3ED3-436C-BE82-78F1BF52E0F8Q78292215-5025C1C8-C25A-427E-86E2-05C724F15C1EQ79832827-5E58810F-A956-4A28-A0A8-1EB9906FE26DQ80651982-C2EF81D1-4423-4C4D-BE48-07722722B6F8Q84151132-04A8CE80-81D7-46A9-B7E7-70D65538DE9AQ86945666-6D6E4F46-3B3A-486F-99F5-73C9254DEACC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ian Marschner
@ast
Ian Marschner
@en
Ian Marschner
@es
Ian Marschner
@nl
type
label
Ian Marschner
@ast
Ian Marschner
@en
Ian Marschner
@es
Ian Marschner
@nl
prefLabel
Ian Marschner
@ast
Ian Marschner
@en
Ian Marschner
@es
Ian Marschner
@nl
P106
P31
P496
0000-0002-6225-1572